Patients and Methods
The study was approved by the the Ethics Committee of Renmin Hospital of
Wuhan University (No. WDRY2020-K019). The requirement for written
informed consent was waived in consideration of emerging infectious
diseases.The study included data from 239 COVID-19 patients in Renmin
Hospital of Wuhan University in China from December 31, 2020 to April
20, 2020. Patients diagnostic criteria about COVID-19: Real-time
fluorescent RT-PCR was used to detect COVID-19 in nasal or pharyngeal
swab specimens, and patients with positive results twice were included
in the study. In addition, relevant clinical symptoms, laboratory
parameters, and major treatments were also included. The outcomes of the
patients included improvement to discharge criteria or worsening to
death. The patient discharge criteria and clinical types shall be based
on the COVID-19 diagnosis and treatment protocol version 6.
Clinical characteristics andtherapeutic modalities
The following clinical symptoms were recruited in the study: 1. The
upper respiratory tract symptoms such as cough, runny nose or sneezing,
2. Oppression in chest or dyspnea , 3. Muscle pain, 4. Headache, 5.
Gastrointestinal symptoms such as nausea, vomiting and diarrhea, 6.
Comorbidities, 7. Body temperature, 8. Time from onset to admission, 9.
Total time in hospital, Comorbidities included a history of pulmonary
basic disease (chronic obstructive pulmonary disease, lung cancer,
bacterial pneumonia, pulmonary heart disease,
et.al),hypertension,coronary artery disease, diabetes,cerebral
infarction. Clinical characters include clinical symptoms, time from
symptom onset to hospitalization, total length of hospitalization,
treatment and medication, and disease outcome.